These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9723380)

  • 21. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group.
    Donahue PE; Smith DL; Yellin AE; Mintz SJ; Bur F; Luke DR
    Am J Surg; 1998 Dec; 176(6A Suppl):53S-61S. PubMed ID: 9935258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.
    Walters DJ; Solomkin JS; Paladino JA
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):551-61. PubMed ID: 10662480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients.
    Deaney NB; Tate H
    J Antimicrob Chemother; 1996 May; 37(5):975-86. PubMed ID: 8737147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation.
    Morales JM; Andrés A; Dominguez-Gil B; Sierra MP; Arenas J; Delgado M; Casal MC; Rodicio L
    Transplant Proc; 2003 May; 35(3 Suppl):154S-156S. PubMed ID: 12742489
    [No Abstract]   [Full Text] [Related]  

  • 25. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
    Hou F; Wu G; Zheng B
    Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in urinary interleukin-2 in kidney transplant recipients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1248-9. PubMed ID: 8658644
    [No Abstract]   [Full Text] [Related]  

  • 27. Nephroprotective effect of cilastatin in allogeneic bone marrow transplantation. Results from a retrospective analysis.
    Gruss E; Tomás JF; Bernis C; Rodriguez F; Traver JA; Fernández-Rañada JM
    Bone Marrow Transplant; 1996 Oct; 18(4):761-5. PubMed ID: 8899192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclosporin conversion to CellCept in a cadaveric renal allograft recipient with hemolytic uremic syndrome.
    Said T; al-Mousawi M; Samhan M; Lao M
    Transplant Proc; 1999 Dec; 31(8):3295-7. PubMed ID: 10616482
    [No Abstract]   [Full Text] [Related]  

  • 29. Reduction of cyclosporine-induced nephrotoxicity by cilastatin following clinical heart transplantation.
    Markewitz A; Hammer C; Pfeiffer M; Zahn S; Drechsel J; Reichenspurner H; Reichart B
    Transplantation; 1994 Mar; 57(6):865-70. PubMed ID: 8154033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of mycophenolate mofetil in renal transplant patients with cyclosporin toxicity.
    Shaheen FA; Sheikh IA
    Transplant Proc; 1999 Dec; 31(8):3294. PubMed ID: 10616481
    [No Abstract]   [Full Text] [Related]  

  • 31. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
    Friemann S; Feuring E; Padberg W; Ernst W
    Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504
    [No Abstract]   [Full Text] [Related]  

  • 32. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 33. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
    Norrby SR; Finch RG; Glauser M
    J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute reversal of cyclosporine nephrotoxicity by neutral endopeptidase inhibition in stable renal transplant recipients.
    Lipkin GW; Thuraisingham R; Dawnay AB; Harwood SM; Raine AE
    Transplantation; 1997 Oct; 64(7):1007-17. PubMed ID: 9381523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis of chronic rejection using peritubular and glomerular capillary lesions.
    Morozumi K; Oikawa T; Fukuda M; Sugito K; Takeuchi O; Oda A; Fujinami T; Takeda A; Uchida K
    Transplant Proc; 1996 Feb; 28(1):508-11. PubMed ID: 8644331
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
    Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplant Proc; 1996 Aug; 28(4):2183-6. PubMed ID: 8769194
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin.
    Böswald M; Döbig C; Kändler C; Krüger C; Scharf J; Soergel F; Zink S; Guggenbichler JP
    Infection; 1999; 27(4-5):299-304. PubMed ID: 10885853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early cyclosporine a withdrawal in kidney transplant recipients under a sirolimus-based immunosuppressive regimen: pathological study of graft biopsies at 1-year posttransplant.
    Ruiz JC; Campistol JM; Mota A; Prats D; Gutiérrez A; Castro A; Pinto JR; García J; Morales JM; Grinyo JM; Arias M
    Transplant Proc; 2002 Feb; 34(1):92-3. PubMed ID: 11959199
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine.
    Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S
    Transplant Proc; 1998 Aug; 30(5):1760-1. PubMed ID: 9723270
    [No Abstract]   [Full Text] [Related]  

  • 40. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients.
    Blume C; Hollenbeck M; Ivens K; Heering P; Hetzel GR; Grabensee B
    Transplant Proc; 2001; 33(7-8):3161-3. PubMed ID: 11750357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.